Last reviewed · How we verify
Five-days oseltamivir + baloxavir marboxil
Five-days oseltamivir + baloxavir marboxil is a Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor) Small molecule drug developed by UMC Utrecht. It is currently in Phase 3 development for Acute uncomplicated influenza in adults and adolescents (treatment).
This combination uses two antiviral agents with different mechanisms to inhibit influenza virus replication through dual targeting of viral neuraminidase and cap-dependent endonuclease.
This combination uses two antiviral agents with different mechanisms to inhibit influenza virus replication through dual targeting of viral neuraminidase and cap-dependent endonuclease. Used for Acute uncomplicated influenza in adults and adolescents (treatment).
At a glance
| Generic name | Five-days oseltamivir + baloxavir marboxil |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor) |
| Target | Influenza neuraminidase; influenza cap-dependent endonuclease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Oseltamivir is a neuraminidase inhibitor that prevents viral release from infected cells by blocking sialic acid cleavage. Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks viral mRNA synthesis at an earlier stage. The combination approach aims to reduce treatment duration while maintaining efficacy and potentially reducing resistance development through dual-mechanism targeting.
Approved indications
- Acute uncomplicated influenza in adults and adolescents (treatment)
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Five-days oseltamivir + baloxavir marboxil CI brief — competitive landscape report
- Five-days oseltamivir + baloxavir marboxil updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about Five-days oseltamivir + baloxavir marboxil
What is Five-days oseltamivir + baloxavir marboxil?
How does Five-days oseltamivir + baloxavir marboxil work?
What is Five-days oseltamivir + baloxavir marboxil used for?
Who makes Five-days oseltamivir + baloxavir marboxil?
What drug class is Five-days oseltamivir + baloxavir marboxil in?
What development phase is Five-days oseltamivir + baloxavir marboxil in?
What are the side effects of Five-days oseltamivir + baloxavir marboxil?
What does Five-days oseltamivir + baloxavir marboxil target?
Related
- Drug class: All Antiviral combination (neuraminidase inhibitor + endonuclease inhibitor) drugs
- Target: All drugs targeting Influenza neuraminidase; influenza cap-dependent endonuclease
- Manufacturer: UMC Utrecht — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Acute uncomplicated influenza in adults and adolescents (treatment)
- Compare: Five-days oseltamivir + baloxavir marboxil vs similar drugs
- Pricing: Five-days oseltamivir + baloxavir marboxil cost, discount & access